Second Affiliated Hospital, School of Medicine, Zhejiang University: Glioblastoma trials

The registry lists 11 Glioblastoma studies with Second Affiliated Hospital, School of Medicine, Zhejiang University as lead sponsor. 7 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 4Phase 2 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term ProgressionRecruitingNCT07670026Phase 2
• Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk GlioblastomaRecruitingNCT07511725Phase 2
• Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent GlioblastomaNot yet recruitingNCT07244666Early Phase 1
• Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced SpreadRecruitingNCT07193654Phase 2
• B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory GlioblastomaRecruitingNCT07193628Phase 1
• Enhanced Adjuvant Therapy for Newly Diagnosed GBM With Partial Surgical Resection or Short-term ProgressionRecruitingNCT06936046Phase 2
• B7-H3 CAR-T for Recurrent or Refractory GlioblastomaRecruitingNCT04077866Phase 1/2
• Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With CadonilimabStatus unknownNCT05737368Phase 1
• Anlotinib Combined With STUPP for MGMT Nonmethylated GlioblastomaStatus unknownNCT04725214Phase 2
• Pilot Study of Elemene in Treating Patients With Refractory GlioblastomaStatus unknownNCT04674527Phase 2
• Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.Status unknownNCT04388033Phase 1/2